Physician profile
Issachar Devine
NPI 1750886503
$6,359.05
in general payments reported to CMS, 2019-2025
18 companies · $4,192 in 2025
The $4,192 reported for 2025 was more than what 96% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $311 · 2023: $558 · 2024: $1,298 · 2025: $4,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,769 · Travel and Lodging: $2,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,768.98 |
| Travel and Lodging | $2,278.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,909.23 | 2024-2025 | Intracept, General - Pain Management |
| Medtronic, INC. | $1,111.77 | 2023-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Globus Medical, INC. | $877.20 | 2025 | Vyrsa V1, Senza |
| Abbott Laboratories | $744.92 | 2025 | Proclaim, Eterna |
| Spr Therapeutics, INC | $524.09 | 2023-2025 | Sprint Pns System |
| Curonix LLC | $407.12 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Spinal Simplicity, LLC | $193.57 | 2022 | |
| Averitas Pharma INC. | $157.61 | 2023 | Qutenza |
| Allergan, INC. | $117.73 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.63 | 2025 | Relistor |
| Nalu Medical, INC. | $49.59 | 2025 | Nalu Neurostimulation System |
| Vertex Pharmaceuticals Incorporated | $43.67 | 2025 | |
| Mml US, INC. | $42.25 | 2025 | Reactiv8 |
| Scilex Pharmaceuticals INC. | $34.85 | 2025 | |
| Protega Pharmaceutials INC | $26.46 | 2025 | Roxybond |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19.38 | 2023 | Botox |
| Fidia Pharma USA INC. | $18.63 | 2025 | Hymovis, Triluron |
| Foundation Fusion Solutions, LLC | $16.35 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Issachar Devine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.